Clinical Trial Update: A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2) [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating afuresertib in combination with carfilzomib for relapsed/refractory multiple myeloma, including dose determination and assessment of …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Afuresertib (afuresertib)
• Carfilzomib (carfilzomib)

Snippet

Sponsor: Novartis | Conditions: Cancer | Phase 1 | Status: TERMINATED